Correa Natasha, Quidwai Ariba, Jeimy Samira, Rondilla Natalie, White Fred, Moote William, Kuprowski Mark, Kim Harold
Division of Clinical Immunology & Allergy, Department of Medicine, Western University, London, ON, N6A 4V2, Canada.
Schulich School of Medicine & Dentistry, Western University, London, ON, N6A 5C1, Canada.
Immunotherapy. 2021 Nov;13(16):1325-1331. doi: 10.2217/imt-2021-0142. Epub 2021 Oct 6.
To determine the safety and efficacy of 0.5 mg intramuscular (IM) epinephrine for the treatment of subcutaneous allergen immunotherapy induced anaphylaxis. Retrospective chart review of patients who received 0.5 mg of IM epinephrine for treatment of anaphylaxis from subcutaneous allergen immunotherapy at two outpatient allergy and immunology practices. Thirty-eight patients received 0.5 mg IM epinephrine. Eleven patients (29%) required a second dose, and two patients (5%) required a third dose of IM epinephrine. Sixteen patients (42%) were transferred to the emergency department with ongoing symptoms. All had eventual resolution of anaphylaxis. There were no adverse reactions or fatalities. IM epinephrine at a dose of 0.5 mg is safe and effective for treatment of anaphylaxis from subcutaneous allergen immunotherapy.
确定0.5毫克肌内注射肾上腺素治疗皮下过敏原免疫疗法诱发的过敏反应的安全性和有效性。对两家门诊过敏与免疫学诊所中接受0.5毫克肌内注射肾上腺素治疗皮下过敏原免疫疗法所致过敏反应的患者进行回顾性病历审查。38例患者接受了0.5毫克肌内注射肾上腺素。11例患者（29%）需要注射第二剂，2例患者（5%）需要注射第三剂肌内注射肾上腺素。16例患者（42%）因症状持续被转至急诊科。所有患者的过敏反应最终均得到缓解。未出现不良反应或死亡情况。0.5毫克剂量的肌内注射肾上腺素治疗皮下过敏原免疫疗法诱发的过敏反应安全有效。
